Inhibition of Siah ubiquitin ligase function

被引:0
|
作者
A Möller
C M House
C S F Wong
D B Scanlon
M C P Liu
Z Ronai
D D L Bowtell
机构
[1] Cancer Genomics and Biochemistry Laboratory,Department of Biochemistry and Molecular Biology
[2] Peter MacCallum Cancer Centre,undefined
[3] University of Melbourne,undefined
[4] Signal Transduction Program,undefined
[5] The Burnham Institute for Medical Research,undefined
来源
Oncogene | 2009年 / 28卷
关键词
ubiquitin; degradation; hypoxia;
D O I
暂无
中图分类号
学科分类号
摘要
Tumor hypoxia induces the upregulation of hypoxia-inducible factor 1α (Hif-1α), which in turn induces the expression of genes including VEGF to recruit new blood vessel outgrowth, enabling tumor growth and metastasis. Interference with the Hif-1 pathway and neoangiogenesis is an attractive antitumor target. The hydroxylation of Hif-1α by prolyl-hydroxylase (PHD) proteins during normoxia serves as a recognition motif for its proteasomal degradation. However, under hypoxic conditions, hydroxylation is inhibited and furthermore, PHD proteins are themselves polyubiquitylated and degraded by Siah ubiquitin ligases. Our data demonstrate for the first time that inhibition of the interaction between Siah and PHD proteins using a fragment derived from a Drosophila protein (phyllopod) interferes with the PHD degradation. Furthermore, cells stably expressing the phyllopod fragment display reduced upregulation of Hif-1α protein levels and Hif-1-mediated gene expression under hypoxia. In a syngeneic mouse model of breast cancer, the phyllopod fragment reduced tumor growth and neoangiogenesis and prolonged survival of the mice. In addition, levels of Hif-1α and its target Glut-1 are reduced in tumors expressing the phyllopod fragment. These data show, in a proof-of-principle study, that Siah protein, the most upstream component of the hypoxia pathway yet identified, is a viable drug target for antitumor therapies.
引用
收藏
页码:289 / 296
页数:7
相关论文
共 50 条
  • [1] Inhibition of Siah ubiquitin ligase function
    Moller, A.
    House, C. M.
    Wong, C. S. F.
    Scanlon, D. B.
    Liu, M. C. P.
    Ronai, Z.
    Bowtell, D. D. L.
    ONCOGENE, 2009, 28 (02) : 289 - 296
  • [2] Inhibition of ubiquitin ligase Siah-1A by disabled-1
    Park, TJ
    Hamanaka, H
    Ohshima, T
    Watanabe, N
    Mikoshiba, K
    Nukina, N
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 302 (04) : 671 - 678
  • [3] A binding motif for Siah ubiquitin ligase
    House, CM
    Frew, IJ
    Huang, HL
    Wiche, G
    Traficante, N
    Nice, E
    Catimel, B
    Bowtell, DDL
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (06) : 3101 - 3106
  • [4] Inhibition studies of Siah2, a ubiquitin ligase, involved in hypoxia induced cancer
    Gopalsamy, Anupriya
    CANCER RESEARCH, 2011, 71
  • [5] The Ubiquitin Ligase Siah2 and the Hypoxia Response
    Nakayama, Koh
    Qi, Jianfei
    Ronai, Ze'ev
    MOLECULAR CANCER RESEARCH, 2009, 7 (04) : 443 - 451
  • [6] Elucidation of the substrate binding site of Siah ubiquitin ligase
    Fedorov, VD
    Parker, MW
    Polekhina, G
    FASEB JOURNAL, 2006, 20 (04): : A492 - A492
  • [7] Elucidation of the substrate binding site of Siah ubiquitin ligase
    House, CM
    Hancock, NC
    Möller, A
    Cromer, BA
    Fedorov, V
    Bowtell, DDL
    Parker, MW
    Polekhina, G
    STRUCTURE, 2006, 14 (04) : 695 - 701
  • [8] Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase SIAH
    Tang, Amy
    Schmidt, Rebecca
    Park, Cheol
    Ahmed, Atique
    Gundelach, Justin
    Reed, Nanette
    Knudsen, Bruce
    Tang, Amy
    CANCER RESEARCH, 2008, 68 (09)
  • [9] The Ubiquitin Ligase Siah2 Regulates PPARγ Activity in Adipocytes
    Kilroy, Gail
    Kirk-Ballard, Heather
    Carter, Lauren E.
    Floyd, Z. Elizabeth
    ENDOCRINOLOGY, 2012, 153 (03) : 1206 - 1218
  • [10] Tumor suppressor function of the ubiquitin ligase Siah1a in melanoma is mediated by myeloid derived suppressor cells
    Scortegagna, Marzia
    Du, Yuanning
    Feng, Yongmei
    Ronai, Ze'ev
    CANCER RESEARCH, 2024, 84 (06)